Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
uTRACE-101: uPAR PET Imaging in Localised Prostate Cancer
NCT06474806Phase 2Recruiting
- Sponsor
- Curasight
- Start
- Jun 2024
- Primary completion
- Jan 2027
- Modality
- Radiopharmaceutical
- Countries
- 3
01
Overview
Phase 2, open-label trial of uTRACE in prostate cancer (PCa) (3 arms), sponsored by Curasight. Primary endpoint: Standard Uptake Value Max at Day 8. Started Jun 2024; status: recruiting.
02
Drugs
uTRACE
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06474806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06474806.